Technical Analysis for OCGN - Ocugen, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Upper Bollinger Band Walk | Strength | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
New 52 Week Closing High | Bullish | -3.54% | |
Pocket Pivot | Bullish Swing Setup | -3.54% | |
Upper Bollinger Band Walk | Strength | -3.54% | |
Wide Bands | Range Expansion | -3.54% | |
Above Upper BB | Strength | -3.54% | |
Overbought Stochastic | Strength | -3.54% | |
Upper Bollinger Band Touch | Strength | -3.54% |
Alert | Time |
---|---|
Down 5% | 1 day ago |
Fell Below Previous Day's Low | 1 day ago |
60 Minute Opening Range Breakdown | 1 day ago |
Possible Inside Day | 1 day ago |
Down 3% | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/21/2024
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Eye Ophthalmology Vision Diabetic Retinopathy Eye Diseases Retina Blindness Retinopathy Host Disease Innovative Therapies Retinitis Graft Versus Host Disease Retinitis Pigmentosa
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Eye Ophthalmology Vision Diabetic Retinopathy Eye Diseases Retina Blindness Retinopathy Host Disease Innovative Therapies Retinitis Graft Versus Host Disease Retinitis Pigmentosa
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.105 |
52 Week Low | 0.345 |
Average Volume | 9,864,900 |
200-Day Moving Average | 0.74 |
50-Day Moving Average | 1.47 |
20-Day Moving Average | 1.52 |
10-Day Moving Average | 1.75 |
Average True Range | 0.18 |
RSI (14) | 62.26 |
ADX | 29.59 |
+DI | 28.30 |
-DI | 11.05 |
Chandelier Exit (Long, 3 ATRs) | 1.51 |
Chandelier Exit (Short, 3 ATRs) | 1.66 |
Upper Bollinger Bands | 2.04 |
Lower Bollinger Band | 1.00 |
Percent B (%b) | 0.87 |
BandWidth | 68.22 |
MACD Line | 0.13 |
MACD Signal Line | 0.08 |
MACD Histogram | 0.0498 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.16 | ||||
Resistance 3 (R3) | 2.17 | 2.10 | 2.12 | ||
Resistance 2 (R2) | 2.10 | 2.03 | 2.09 | 2.10 | |
Resistance 1 (R1) | 2.00 | 1.99 | 1.97 | 1.99 | 2.09 |
Pivot Point | 1.93 | 1.93 | 1.91 | 1.93 | 1.93 |
Support 1 (S1) | 1.84 | 1.87 | 1.80 | 1.83 | 1.73 |
Support 2 (S2) | 1.77 | 1.83 | 1.76 | 1.72 | |
Support 3 (S3) | 1.67 | 1.77 | 1.70 | ||
Support 4 (S4) | 1.66 |